VC firms
Aditum Bio is a new model of biotech venture capital, uniquely positioned to rapidly translate scientific discoveries into innovative new medicines.
Overview
Investment Type
Venture Capital
Portfolio 1
| Date | Name | Website | Total Raised | Location |
| Sign up to see | Sign up to see | Sign up to see | Sign up to see | Sign up to see |
Mentions in press and media 11
| Date | Title | Description |
| Sign up to see | Sign up to see | Sign up to see |
| Jun 27, 2026 | Oblenio Bio Raises $62 Million Series B To Advance Autoimmune Disease Therapy | Oblenio Bio announced that it has closed an oversubscribed $62 million Series B financing round to advance its lead autoimmune disease program into clinical development. The round was led by Pfizer Ventures, with participation from new inve... |
| Mar 24, 2026 | Fosun Pharma Announces 2025 Annual Results | Innovation and Globalization Propel Fosun Pharma's High-Quality Growth SHANGHAI, March 24, 2026 /PRNewswire/ -- On 24 March, 2026, Fosun Pharma ("the company", stock code: 600196.SH; 02196.HK), an innovation-driven global pharmace... |
| Sep 17, 2025 | Mabwell Bioscience and Aditum Bio Announce Formation of Kalexo Bio to Advance Innovative siRNA Therapy for Cardiovascular Disorders | SHANGHAI and OAKLAND, Calif., Sept. 17, 2025 /PRNewswire/ -- Mabwell (Shanghai) Bioscience Co., Ltd. (688062.SH) and Aditum Bio today announced the launch of Kalexo Bio, a new company formed in conjunction with an exclusive global license a... |
| Jul 31, 2025 | Leads Biolabs’ IPO points to biotech rebound in Hong Kong | Header photo source: Hong Kong Stock Exchange. On July 25, Leads Biolabs made its official debut on the Hong Kong Stock Exchange. Its shares surged as much as 117% intraday before closing up more than 90%, giving the biotech firm a market c... |
| Jul 25, 2025 | Leads Biolabs Lists on HKEX, Raising USD 189 Million Through Initial Public Offering | NANJING, China, July 25, 2025 /PRNewswire/ -- On 25 July, 2025 (China Time), Nanjing Leads Biolabs Co., Ltd. ("Leads Biolabs" or the "Company") listed on the Main Board of The Stock Exchange of Hong Kong Limited (HKEX) u... |
| Nov 7, 2024 | Aditum Bio and Leads Biolabs Announce the Formation of Oblenio Bio to Develop a Tri-Specific T-Cell Engager for Autoimmune Disorders | Leads Biolabs grants Oblenio Bio an exclusive option to license LBL-051, a first-in-class CD19xBCMAxCD3 tri-specific T-cell engager antibody OAKLAND, Calif. and NANJING, China, Nov. 7, 2024 /PRNewswire/ -- Aditum Bio and Leads Biolabs today... |
| Sep 21, 2023 | Inmagene announces formation of Celexor Bio based on its anti-ILT7 mAb with enhanced pDC depletion function | SAN DIEGO, Sept. 21, 2023 /PRNewswire/ -- Inmagene Biopharmaceuticals (Inmagene), a clinical-stage biotech company developing innovative and differentiated therapies for immunological and inflammatory diseases, today announced its partnersh... |
| Sep 7, 2021 | Via Nova Therapeutics Announces $20 Million Series A Financing from Aditum Bio to Advance Four Antiviral Programs | |
| Jun 30, 2021 | Aditum Bio Announces Formation of Ancora Bio, to Focus on Treatment-Resistant Depression |
Show more
Reviews 0
FAQ about Aditum Bio
How many startups has Aditum Bio invested in?
Aditum Bio has 1 portfolio company on Parsers VC.
What has the press written about Aditum Bio?
Parsers VC has collected 11 articles mentioning Aditum Bio, among them “Oblenio Bio Raises $62 Million Series B To Advance Autoimmune Disease Therapy” (Jun 27, 2026) and “Fosun Pharma Announces 2025 Annual Results” (Mar 24, 2026).
Is Aditum Bio still active?
Yes, Aditum Bio is active; its latest activity on Parsers VC dates from Jun 27, 2026.